Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study

Abelson, Mark B.; Gomes, Paul J; Vogelson, C.T.; Pasquine, T.A.; Gross, Robert D.; Turner, Frederic; Wells, David T.; Bergamini, Michael V.W.; Robertson, S.M.

doi:10.1016/s0149-2918(04)80065-1

Cited by 39 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Simultaneous analysis of pollen level (frequency based) and pollen period (severity based) was performed to account for influence of environmental variables on clinical differences in ocular itching and redness between treatment groups [52]. Results revealed olopatadine 0.2% was associated with significant reductions in calculated mean scores for ocular itching and redness by pollen level and by pollen period [52]. A similar three-armed trial contrasting olopatadine HCl 0.1% versus ketotifen fumarate 0.025% versus artificial tear substitute in patients with seasonal allergic conjunctivitis.…”

Section: Dual Action Agent Versus Placebo or Dual Action Agentmentioning

confidence: 99%

Pharmacology of ocular allergy

Schultz

2006

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Important pharmacologic properties of targets have been revealed. First, histamine is more specifically antagonized by second generation antihistamines. Second, newly formed mediators and downstream responders (prostaglandins, leukotrienes, interleukins, intercellular adhesion molecule 1, tumor necrosis factor, vascular cell adhesion molecule, eosinophils and neutrophils) are more selectively antagonized by dual/multiple-action agents.

show abstract

Section: Dual Action Agent Versus Placebo or Dual Action Agentmentioning

confidence: 99%

Pharmacology of ocular allergy

Schultz

2006

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…A. с соавт [17,18]. Было продемон-стрировано, что мононуклеары периферической крови плода способны отвечать на контакт со специфическими аллергенами, начиная с 22 недели гестации, и интенсив-ность ответа возрастает с увеличением гестационного возраста.…”

Section: Issn 1816-5095 (Print); Issn 2500-0845 (Online) Doi: 101800unclassified

“…Олопатадин 0,2% имеет концентрацию олопатадина, в два раза превышающую его концентрацию в известном препарате Опатанол® (олопатадин 0,1%). Препарат Визаллергол® применяют один раз в сутки для лечения зуда и покраснения в об-ласти век, связанных с аллергическим конъюнктивитом [18,19]. Препарат характеризуется длительным сроком действия -до 24 часов [20].…”

Section: Issn 1816-5095 (Print); Issn 2500-0845 (Online) Doi: 101800unclassified

Allergic Eye Diseases in Children. Modern View on Pathogenesis and Treatment

Маркова¹,

Полунина²,

Иойлева³

2017

test

View full text Add to dashboard Cite

“…the safety and efficacy of olopatadine has been shown in active-and placebo-controlled trials. [47][48][49] the efficacy of olopatadine 0.1 % was compared with levocabastine 0.05 % in a cac study. 50 Subjects were bilaterally challenged with an allergen 27 minutes after topical drug administration, and the first postchallenge assessment was carried out 3 minutes later, or 30 minutes after instillation of the drug.…”

Section: Mechanism Of Action Of Dual-acting Agents In Ocular Allergymentioning

confidence: 99%

“…a 10-week, randomized, placebo-controlled trial to determine the efficacy and safety of 0.2 % olopatadine QD in the treatment of ac or rhinoconjunctivitis was conducted in 260 patients. 48 this environmental study assessed ocular signs and symptoms in terms of frequency (whole-unit scale from 0 to 5) and severity (half-unit scale from 0 to 4); grass pollen counts were also assessed daily. analyses of ocular itching and redness showed that when grass pollen counts were high, a respective 21 % and 14 % of patients in the olopatadine 0.2 % group assessed the frequency of ocular itching and redness as >grade 2 compared with 47 % and 31 % of patients in the placebo group (p<0.001 for ocular itching; p<0.003 for redness, respectively).…”

Section: Mechanism Of Action Of Dual-acting Agents In Ocular Allergymentioning

confidence: 99%

Topical Corticosteroids and Antihistamines—Mast Cell Stabilizers for the Treatment of Allergic Conjunctivitis

Gong¹,

Blaiss²

2013

US Ophthalmic Review

View full text Add to dashboard Cite

ocular allergy is one of the most frequently encountered conditions in clinical eye care-epidemiologic reports have shown that it affects up to 60 million uS citizens. 1 The eye, being continually exposed to the external environment, is a common site of allergic inflammation. The classic clinical signs of this inflammation are seen in the conjunctiva. allergic conjunctivitis (ac) manifests as a immunoglobulin E (igE) hypersensitivity reaction that occurs when the ocular surface is exposed to external antigens. [2][3][4] These antigens include airborne pollen, animal dander, and other environmental antigens. 3,5 Even though these environmental antigens are not always threats to the ocular surface, they elicit an inappropriate adaptive immune response in some individuals, leading to this hypersensitivity reaction. Sac is most commonly caused due to exposure to pollens from grasses, trees, ragweed, or other seasonal plants. it therefore tends to occur frequently in spring and autumn, which are seasons associated with higher levels of these airborne allergens. 11 While the most obvious solution would be avoidance of the causative agents, this may not always be practical. The most commonly used nonpharmacologic interventions include cold compresses, lubrication, such as artificial tears, and the daily disposal of contact lenses in patients who are wearers. 12 Saline eye drops have been described as effective in reducing signs and symptoms in 30-35 % of cases. 13,14 AbstractThe most common ocular manifestation of allergy, allergic conjunctivitis (ac), is the result of a hypersensitivity response occurring after exposure of the ocular surface to airborne antigens. Treatment options for ac comprise antihistamines, mast cell stabilizers, dual-acting mast cell stabilizer-antihistamines, corticosteroids, nonsteroidal anti-inflammatory drugs (NSaids), and combinations thereof. despite clinical evidence to support the use of antihistamines, such as levocabastine, antihistamines are unable to mitigate all symptoms of ac because histamine is not the only mediator released during the allergic inflammatory response and has no direct effect on inflammatory cells involved in clinical symptoms. dual-acting mast cell stabilizer-antihistamines, such as bepotastine, alcafatidine, epinastine, ketotifen, and olopatadine, have a broader effect than antihistamines alone. corticosteroids inhibit the entire inflammatory cascade and therefore offer the most complete option for ac, although their use has been limited due to concerns about increased intraocular pressure (ioP) and the potential for cataract formation with extended use. loteprednol etabonate (lE) has a decreased effect on ioP and cannot form Schiff base intermediates with lens protein, which is considered a first step in cataractogenesis. The efficacy and safety of lE in the treatment of seasonal ac (Sac) has been demonstrated in clinical trials.

show abstract

Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study

Cited by 39 publications

References 15 publications

Pharmacology of ocular allergy

Pharmacology of ocular allergy

Allergic Eye Diseases in Children. Modern View on Pathogenesis and Treatment

Topical Corticosteroids and Antihistamines—Mast Cell Stabilizers for the Treatment of Allergic Conjunctivitis

Contact Info

Product

Resources

About